Autologous graft-versus-host disease.
Treatment with cyclosporine A, a prototypic immunosuppressive drug, following autologous bone marrow transplantation (autoBMT) induces autologous graft-versus-host disease (autoGvHD), similar to acute GvHD after allogeneic BMT. The development of autoGvHD appears to be associated with the emergence of autoreactive T cells recognizing self MHC class II antigens and the elimination of a T-cell-dependent peripheral autoregulatory mechanism. The induction of autoGvHD may be of benefit to the autoBMT patients by providing the graft-versus-tumor effect.
Karasuno
T
T
Fifth Department of Medicine, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan.
D016026:Bone Marrow Transplantation; D016572:Cyclosporine / Q000009:adverse effects; D006086:Graft vs Host Disease; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects; D014182:Transplantation, Autologous
D007166:Immunosuppressive Agents; D016572:Cyclosporine